228 related articles for article (PubMed ID: 30797684)
1. Synergistic effects of tea polyphenol epigallocatechin 3-O-gallate and azole drugs against oral Candida isolates.
Behbehani JM; Irshad M; Shreaz S; Karched M
J Mycol Med; 2019 Jun; 29(2):158-167. PubMed ID: 30797684
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of tea catechin epigallocatechin gallate and antimycotics against oral Candida species.
Ning Y; Ling J; Wu CD
Arch Oral Biol; 2015 Oct; 60(10):1565-70. PubMed ID: 26263544
[TBL] [Abstract][Full Text] [Related]
3. Tea polyphenol epigallocatechin-3-gallate inhibits ergosterol synthesis by disturbing folic acid metabolism in Candida albicans.
Navarro-Martínez MD; García-Cánovas F; Rodríguez-López JN
J Antimicrob Chemother; 2006 Jun; 57(6):1083-92. PubMed ID: 16585130
[TBL] [Abstract][Full Text] [Related]
4. The natural compound magnolol affects growth, biofilm formation, and ultrastructure of oral Candida isolates.
Behbehani J; Shreaz S; Irshad M; Karched M
Microb Pathog; 2017 Dec; 113():209-217. PubMed ID: 29074435
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of 23 tea extractions and epigallocatechin gallate against Candida species.
Chen M; Zhai L; Arendrup MC
Med Mycol; 2015 Feb; 53(2):194-8. PubMed ID: 25605775
[TBL] [Abstract][Full Text] [Related]
6. Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts.
Park BJ; Park JC; Taguchi H; Fukushima K; Hyon SH; Takatori K
Biochem Biophys Res Commun; 2006 Aug; 347(2):401-5. PubMed ID: 16831406
[TBL] [Abstract][Full Text] [Related]
7. Multiple effects of green tea catechin on the antifungal activity of antimycotics against Candida albicans.
Hirasawa M; Takada K
J Antimicrob Chemother; 2004 Feb; 53(2):225-9. PubMed ID: 14688042
[TBL] [Abstract][Full Text] [Related]
8. Anticandidal Activity of Capsaicin and Its Effect on Ergosterol Biosynthesis and Membrane Integrity of
Behbehani JM; Irshad M; Shreaz S; Karched M
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674560
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antifungal activity of statin-azole associations as witnessed by Saccharomyces cerevisiae- and Candida utilis-bioassays and ergosterol quantification.
Cabral ME; Figueroa LI; Fariña JI
Rev Iberoam Micol; 2013 Jan; 30(1):31-8. PubMed ID: 23069981
[TBL] [Abstract][Full Text] [Related]
10. In vitro study on the potential fungicidal effects of atorvastatin in combination with some azole drugs against multidrug resistant Candida albicans.
Mahmoud DE; Faraag AHI; Abu El-Wafa WM
World J Microbiol Biotechnol; 2021 Oct; 37(11):191. PubMed ID: 34632522
[TBL] [Abstract][Full Text] [Related]
11. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients.
Chavanet P; Lopez J; Grappin M; Bonnin A; Duong M; Waldner A; Buisson M; Camerlynck P; Portier H
AIDS; 1994 Jul; 8(7):945-50. PubMed ID: 7946104
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of tacrolimus and azole antifungal compounds in fluconazole-susceptible and fluconazole-resistant Candida glabrata isolates.
Denardi LB; Mario DA; Loreto ÉS; Santurio JM; Alves SH
Braz J Microbiol; 2015 Mar; 46(1):125-9. PubMed ID: 26221097
[TBL] [Abstract][Full Text] [Related]
13. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis.
Johnson EM; Warnock DW; Luker J; Porter SR; Scully C
J Antimicrob Chemother; 1995 Jan; 35(1):103-14. PubMed ID: 7768758
[TBL] [Abstract][Full Text] [Related]
14. Origin of differences in susceptibility of Candida krusei to azole antifungal agents.
Marichal P; Gorrens J; Coene MC; Le Jeune L; Vanden Bossche H
Mycoses; 1995; 38(3-4):111-7. PubMed ID: 7477085
[TBL] [Abstract][Full Text] [Related]
15. Antifungal Activity of Capric Acid, Nystatin, and Fluconazole and Their
Khalandi H; Masoori L; Farahyar S; Delbandi AA; Raiesi O; Farzanegan A; Khalandi G; Mahmoudi S; Erfanirad T; Falahati M
Assay Drug Dev Technol; 2020; 18(4):195-201. PubMed ID: 32392426
[TBL] [Abstract][Full Text] [Related]
16. In vitro antifungal synergy between amphiphilic aminoglycoside K20 and azoles against Candida species and Cryptococcus neoformans.
Shrestha SK; Grilley M; Anderson T; Dhiman C; Oblad J; Chang CW; Sorensen KN; Takemoto JY
Med Mycol; 2015 Nov; 53(8):837-44. PubMed ID: 26260746
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Antifungal Activity of
Tullio V; Roana J; Scalas D; Mandras N
Molecules; 2019 Aug; 24(17):. PubMed ID: 31470602
[TBL] [Abstract][Full Text] [Related]
18. Effect of chlorogenic and gallic acids combined with azoles on antifungal susceptibility and virulence of multidrug-resistant Candida spp. and Malassezia furfur isolates.
Rhimi W; Aneke CI; Annoscia G; Otranto D; Boekhout T; Cafarchia C
Med Mycol; 2020 Nov; 58(8):1091-1101. PubMed ID: 32236482
[TBL] [Abstract][Full Text] [Related]
19. Reduced azole susceptibility in genotype 3 Candida dubliniensis isolates associated with increased CdCDR1 and CdCDR2 expression.
Pinjon E; Jackson CJ; Kelly SL; Sanglard D; Moran G; Coleman DC; Sullivan DJ
Antimicrob Agents Chemother; 2005 Apr; 49(4):1312-8. PubMed ID: 15793103
[TBL] [Abstract][Full Text] [Related]
20. In vitro antifungal activity of epigallocatechin 3-O-gallate against clinical isolates of dermatophytes.
Park BJ; Taguchi H; Kamei K; Matsuzawa T; Hyon SH; Park JC
Yonsei Med J; 2011 May; 52(3):535-8. PubMed ID: 21488200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
